Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

NCT02862431 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped manufacturing-related issues

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: JNJ-64565111
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC